1
Donald J Graham: Support device for a disposable trash bag. Roland T Bryan, January 9, 1990: US04892224 (52 worldwide citation)

A trash entry chute device for mounting on a top-opening trash container, which device supports and holds open a limp plastic film bag for use as a disposable liner for the container. The device comprises a chute having a flange which supports the device on the container and diverts trash into the c ...


2
Jon H Condra, Donald J Graham, Leah Gotlib: Color screening assay for identifying inhibitor resistant HIV protease mutants. Merck & Co, Roy D Meredith, Charles M Caruso, July 25, 1995: US05436131 (15 worldwide citation)

A chromogenic assay is described for the identification and isolation of drug-resistant HIV protease mutants. Coversely, the assay is useful to screen for new inhibitors of HIV protease, e.g., inhibitors not affected by drug-resistance of the HIV protease. This color screening assay contains a vecto ...


3
Steven W Ludmerer, Donald J Graham, Robert L LaFemina, Osvaldo A Flores, Maura Pizzuti, Cinzia Traboni: HCV replicons containing NS5B from genotype 2B. Merck Sharp & Dohme, Istituto di Richerche di Biologia Molecolare P Angeletti S p A, Melissa B Wenk, Sheldon O Heber, January 15, 2013: US08354518

The present invention features methods for enhancing the ability of a genotype 2b NS5B sequence to function in a replicon, for producing replicons containing a functional genotype 2b NS5B, and for using replicons to measure the ability of a compound to affect HCV replication that is sustained with t ...


4
Donald J Graham, Amy L Simcoe, Steven W Ludmerer, Osvaldo A Flores, Robert L LaFemina: HCV RNA-dependent RNA polymerase. Merck & Co, Melissa B Wenk, Sheldon O Heber, August 4, 2009: US07569374

The present invention features NS5B polypeptides from different clinically important HCV genotypes. The polypeptides can be used individually, or as part of a panel of RNA-dependent RNA polymerases, to evaluate the effectiveness of a compound to inhibit NS5B activity.


5
Donald J Graham, Amy L Simcoe, Steven W Ludmerer, Osvaldo A Flores, Robert L LaFemina: HCV RNA-dependent RNA polymerase. Merck & Co, Melissa B Wenk, Sheldon O Heber, February 12, 2008: US07329732

The present invention features NS5B polypeptides from different clinically important HCV genotypes. The polypeptides can be used individually, or as part of a panel of RNA-dependent RNA polymerases, to evaluate the effectiveness of a compound to inhibit NS5B activity.


6
Donald J Graham, Amy L Simcoe, Steven W Ludmerer, Osvaldo A Flores, Robert L LaFemina: Hcv rna dependent rna polymerase. Merck And Co, June 28, 2007: US20070149761-A1

The present invention features NS5B polypeptides from different clinically important HCV genotypes. The polypeptides can be used individually, or as part of a panel of RNA-dependent RNA polymerases, to evaluate the effectiveness of a compound to inhibit NS5B activity.


7
Donald J Graham, Amy L Simcoe, Steven W Ludmerer, Osvaldo A Flores, Robert L LaFemina: HCV RNA-dependent RNA polymerase. Merck And Co, August 7, 2008: US20080187903-A1

The present invention features NS5B polypeptides from different clinically important HCV genotypes. The polypeptides can be used individually, or as part of a panel of RNA-dependent RNA polymerases, to evaluate the effectiveness of a compound to inhibit NS5B activity.


8
Steven W Ludmerer, Donald J Graham, Robert L Lafemina, Osvaldo A Flores, Maura Pizzuti, Cinzia Traboni: Hcv replicons containing ns5b from genotype 2b. October 13, 2011: US20110250628-A1

The present invention features methods for enhancing the ability of a genotype 2b NS5B sequence to function in a replicon, for producing replicons containing a functional genotype 2b NS5B, and for using replicons to measure the ability of a compound to affect HCV replication that is sustained with t ...


9
Steven W Ludmerer, Donald J Graham, David B Olsen, Warren E Glaab: In vivo hcv resistance to anti-viral inhibitors. Merck, June 10, 2010: US20100143886-A1

HCV mutations emerged in chimpanzees treated with a N5B polymerase inhibitor (Compound A) or a NS3 protease inhibitor (Compound B). Short term treatment with Compound A was followed by the initial emergence of an HCV with a S282T polymerase mutation following treatment. Short term treatment with Com ...


10
Steven W Ludmerer, Donald J Graham, David B Olsen: Rapid method to determine inhibitor sensitivity of NS3/4A protease sequences cloned from clinical samples. Merck And Co, August 13, 2009: US20090203008-A1

A method for measuring HCV NS3/4A activity from a HCV NS3/4A sequence, comprising obtaining and cloning the sequence into a mammalian expression vector, transiently transfecting a mammalian cell with the vector, which includes a reporter construct encoding a HCV NS3/4A cleavage site fused to a detec ...